

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	
Company	General
AbbVie (epcoritamab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia TrustAnthony Nolan	 Board of Community Health Councils in Wales
 Black Health Agency for Equality 	British National Formulary
	Care Quality Commission
Cancer Black Care	Department of Health – Northern Ireland
Cancer52	Healthcare Improvement Scotland
Follicular Lymphoma FoundationHelen Rollason Cancer Charity	 Medicines and Healthcare products Regulatory Agency
Independent Cancer Patients Voice	National Association of Primary Care
Kevin Kararwa Leukaemia Trust	National Pharmacy Association
Leukaemia Cancer Society	NHS Confederation
Leukaemia Care	Scottish Medicines Consortium
Leukaemia UK	 Welsh Government
Lymphoma Action	Welsh Health Specialised Services Committee
Macmillan Cancer Support	Committee
Maggie's Centres	Comparator companies
Marie Curie	<u>Comparator companies</u>
South Asian Health Foundation	Advanz Pharma (lenalidomide)
Specialised Healthcare Alliance	Amarox (lenalidomide)
Tenovus Cancer Care	Biocon Pharma (lenalidomide)
	Bristol Myers Squibb (lenalidomide,
Healthcare professional groups	lisocabtagene maraleucel)
Association of Cancer Physicians	 Celltrion Healthcare (rituximab)
British Geriatrics Society	 Dr Reddy's Laboratories
British Institute of Radiology	(bendamustine)
 British Oncology Pharmacy 	Grindeks Kalceks UK (lenalidomide)
Association	• Mylan (lenalidomide)
British Psychosocial Oncology Society	 Pfizer (rituximab)
	 Piramal Critical Care (lenalidomide)
British Society for Haematology	 Roche (obinutuzumab, rituximab)
British Society of Interventional	
Radiology	Sandoz (lenalidomide, rituximab)
British Transplantation Society	Seacross Pharmaceuticals
	(bendamustine)

Provisional stakeholder list for the evaluation of epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] Issue date: February 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Cancer Research UK	 Sun Pharma (lenalidomide)
NHS Blood and Transplant	 Teva UK (lenalidomide)
Royal College of General Practitioners	Thornton & Ross (lenalidomide)
Royal College of Nursing	 Zentiva (bendamustine)
Royal College of Pathologists	
Royal College of Physicians	Relevant research groups
Royal College of Radiologists	Cochrane Haematology Group
Royal Pharmaceutical Society	 Genomics England
Royal Society of Medicine	 Institute of Cancer Research
Society and College of Radiographers	Leukaemia Busters
UK Clinical Pharmacy Association	 Lymphoma Research Trust
UK Cutaneous Lymphoma Group	MRC Clinical Trials Unit
UK Oncology Nursing Society	 National Cancer Research Institute High Grade Lymphoma Subgroup
Others	 National Institute for Health Research
Department of Health and Social Care	
 NHS England 	Associated Public Health group
	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG). Provisional stakeholder list for the evaluation of epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] Issue date: February 2025 © National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.